Trials / Completed
CompletedNCT00636909
Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders
Nonmyeloablative Allogeneic Stem Cell Transplant for the Treatment of Hematologic Disorders
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Beth Israel Deaconess Medical Center · Academic / Other
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to provide allogeneic stem cell transplantation to patients who have not traditionally undergone this procedure because of it high incidence of treatment related side effects. We hope to decrease these side effects by decreasing the chemotherapy dose prior to transplant (non-myeloablative, smaller dose of chemotherapy given so bone marrow is not completely eliminated) and by using donated stem cells to treat cancer of the blood.
Conditions
- AML
- ALL
- CML Chronic Phase, Accelerated Phase, or Blast Crisis
- CLL
- MDS
- RELAPSED NON-HODGKIN'S OR HODGKIN'S LYMPHOMA
- APLASTIC ANEMIA
- MULTIPLE MYELOMA
- MYELOPROLIFERATIVE DISORDER (P Vera, CMML, ET)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cyclophosphamide | preparative cytoreduction |
| DRUG | fludarabine | preparative cytoreduction |
| DRUG | cyclosporine | immunosuppressive therapy |
| DRUG | methotrexate | immunosuppressive therapy |
| BIOLOGICAL | G-CSF | foster engraftment |
Timeline
- Start date
- 1999-07-01
- Primary completion
- 2006-03-01
- First posted
- 2008-03-17
- Last updated
- 2017-04-06
Source: ClinicalTrials.gov record NCT00636909. Inclusion in this directory is not an endorsement.